Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018165037) USE OF POLYMETHOXYLATED FLAVONES TO AMELIORATE CIRCADIAN RHYTHM DISORDERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/165037 International Application No.: PCT/US2018/020944
Publication Date: 13.09.2018 International Filing Date: 05.03.2018
IPC:
A61K 31/352 (2006.01) ,A61P 3/10 (2006.01) ,A61P 3/06 (2006.01) ,A61P 3/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
352
condensed with carbocyclic rings, e.g. cannabinols, methantheline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
06
Antihyperlipidemics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
Applicants:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street Austin, TX 78701, US
Inventors:
CHEN, Zheng; US
YOO, Seung-Hee; US
TAKAHASHI, Joseph, S.; US
Agent:
EICH, Raymund, F.; US
Priority Data:
62/468,22707.03.2017US
Title (EN) USE OF POLYMETHOXYLATED FLAVONES TO AMELIORATE CIRCADIAN RHYTHM DISORDERS
(FR) UTILISATION DE FLAVONES POLYMÉTHOXYLÉES POUR AMÉLIORER LES TROUBLES DU RYTHME CIRCADIEN
Abstract:
(EN) Disclosed are methods comprising administering to a mammal suffering from, or at risk of suffering from, a clock-controlled disorder, such as metabolic syndrome or a constituent condition thereof, a composition comprising at least one polymethoxylated flavone. Disclosed are methods comprising administering a composition comprising at least one polymethoxylated flavone to a mammal suffering from or at risk of suffering from a sleep disorder; suffering from aging; and/or suffering from or at risk of suffering from a mood disorder. The polymethoxylated flavone may be nobiletin and/or tangeretin. The composition may also comprise other compounds, such as nicotinamide riboside and/or pterostilbene, and/or other compounds expected to improve one or more symptoms of metabolic syndrome, a sleep disorder, a mood disorder, aging, a cardiovascular disease, an immune disorder, a neurodegenerative disease, and/or a cancer.
(FR) L'invention concerne des procédés consistant à administrer à un mammifère souffrant ou risquant de souffrir d'un trouble régulé par l'horloge circadienne, tel que le syndrome métabolique ou un état constitutif de celui-ci, d'une composition comprenant au moins une flavone polyméthoxylée. L'invention concerne des procédés consistant à administrer une composition comprenant au moins une flavone polyméthoxylée à un mammifère souffrant ou risquant de souffrir d'un trouble du sommeil ; souffrant du vieillissement ; et/ou souffrant ou présentant un risque de souffrir d'un trouble de l'humeur. La flavone polyméthoxylée peut être la nobilétine et/ou la tangérétine. La composition peut également comprendre d'autres composés, tels que le nicotinamide riboside et/ou le ptérostilbène, et/ou d'autres composés prévus pour soulager un ou plusieurs symptômes du syndrome métabolique, d'un trouble du sommeil, d'un trouble de l'humeur, du vieillissement, d'une maladie cardiovasculaire, d'un trouble immunitaire, d'une maladie neurodégénérative et/ou d'un cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)